Coya Therapeutics Reports Additional Proof-of-Concept Clinic

The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of low-dose interleukin 2 (ld IL-2) in 8 patients with Alzheimer’s disease (AD). The academic study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital.The additional cl...

Related Keywords

Houston , Texas , United States , Amsterdam , Noord Holland , Netherlands , Americans , Stanley Appel , David Snyder , Nasdaq , Alzheimer Association International Conference , Alzheimer Association , Centers For Disease , Gates Foundation , Coya Therapeutics Inc , Houston Methodist , Mini Mental State Examination , Disease Assessment Scale , Cognitive Subscale , Clinical Dementia Rating Sum , Coya Therapeutics , Association International Conference , Houston Methodist Hospital , Scientific Advisory Board , Disease Control ,